Klotho Neurosciences (KLTO) Competitors $0.43 -0.02 (-5.27%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrends KLTO vs. SABS, OTLK, SRZN, CRIS, PLUR, SNTI, INKT, CLDI, ATHA, and INABShould you be buying Klotho Neurosciences stock or one of its competitors? The main competitors of Klotho Neurosciences include SAB Biotherapeutics (SABS), Outlook Therapeutics (OTLK), Surrozen (SRZN), Curis (CRIS), Pluri (PLUR), Senti Biosciences (SNTI), MiNK Therapeutics (INKT), Calidi Biotherapeutics (CLDI), Athira Pharma (ATHA), and IN8bio (INAB). These companies are all part of the "biological products, except diagnostic" industry. Klotho Neurosciences vs. SAB Biotherapeutics Outlook Therapeutics Surrozen Curis Pluri Senti Biosciences MiNK Therapeutics Calidi Biotherapeutics Athira Pharma IN8bio SAB Biotherapeutics (NASDAQ:SABS) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends. Does the MarketBeat Community believe in SABS or KLTO? SAB Biotherapeutics received 27 more outperform votes than Klotho Neurosciences when rated by MarketBeat users. CompanyUnderperformOutperformSAB BiotherapeuticsOutperform Votes2781.82% Underperform Votes618.18%Klotho NeurosciencesN/AN/A Do institutionals & insiders believe in SABS or KLTO? 7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 20.1% of Klotho Neurosciences shares are owned by institutional investors. 26.5% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 2.0% of Klotho Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is SABS or KLTO more profitable? Klotho Neurosciences has a net margin of 0.00% compared to SAB Biotherapeutics' net margin of -1,450.14%. Klotho Neurosciences' return on equity of -1.48% beat SAB Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics-1,450.14% -94.37% -67.26% Klotho Neurosciences N/A -1.48%-25.89% Do analysts rate SABS or KLTO? SAB Biotherapeutics presently has a consensus price target of $12.40, indicating a potential upside of 166.67%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe SAB Biotherapeutics is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Klotho Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer SABS or KLTO? In the previous week, SAB Biotherapeutics' average media sentiment score of 0.00 equaled Klotho Neurosciences'average media sentiment score. Company Overall Sentiment SAB Biotherapeutics Neutral Klotho Neurosciences Neutral Which has preferable valuation and earnings, SABS or KLTO? Klotho Neurosciences has lower revenue, but higher earnings than SAB Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSAB Biotherapeutics$2.24M19.16-$42.19MN/AN/AKlotho NeurosciencesN/AN/A$1.35MN/AN/A SummarySAB Biotherapeutics beats Klotho Neurosciences on 6 of the 11 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Klotho Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLTO vs. The Competition Export to ExcelMetricKlotho NeurosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.76M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7390.1317.19Price / SalesN/A415.011,116.25117.05Price / Cash1.09182.1043.1037.85Price / Book-0.203.894.784.78Net Income$1.35M-$42.21M$120.31M$225.60M7 Day Performance1.14%-2.15%-1.92%-1.23%1 Month Performance23.87%1.73%13.65%0.46%1 Year PerformanceN/A16.36%28.34%15.24% Klotho Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLTOKlotho NeurosciencesN/A$0.43-5.3%N/AN/A$9.76MN/A0.00N/AGap DownSABSSAB Biotherapeutics2.4238 of 5 stars$3.83-6.1%$12.40+223.8%+532.7%$35.35M$2.24M0.00140Gap UpOTLKOutlook Therapeutics1.8305 of 5 stars$1.45-2.0%$42.34+2,819.2%-83.2%$34.32MN/A0.0020SRZNSurrozen1.0796 of 5 stars$10.09+2.4%N/A+34.0%$32.79M$10M0.0042CRISCuris2.5237 of 5 stars$3.47-2.8%$23.00+562.8%-75.7%$29.38M$10.26M-0.4849PLURPluri0.4276 of 5 stars$4.69-0.6%N/A+5.9%$26.08M$330,000.000.00150News CoverageSNTISenti Biosciences2.3348 of 5 stars$5.22-6.3%$10.00+91.6%-9.6%$23.96M$2.56M-0.334News CoverageGap DownINKTMiNK Therapeutics2.2338 of 5 stars$0.58-5.8%$6.50+1,019.7%-48.4%$22.96MN/A-1.4930Gap UpCLDICalidi Biotherapeutics2.3407 of 5 stars$1.75-5.4%$16.67+852.4%N/A$22.89M$50,000.000.0041News CoverageGap DownATHAAthira Pharma2.1034 of 5 stars$0.57-2.9%$13.83+2,335.0%-71.9%$21.97MN/A-0.2140INABIN8bio3.644 of 5 stars$0.30+4.1%$7.75+2,514.7%-80.7%$21.48MN/A-0.3820Gap Down Related Companies and Tools Related Companies SAB Biotherapeutics Competitors Outlook Therapeutics Competitors Surrozen Competitors Curis Competitors Pluri Competitors Senti Biosciences Competitors MiNK Therapeutics Competitors Calidi Biotherapeutics Competitors Athira Pharma Competitors IN8bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KLTO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
